Clinical Trials

VALBIOTIS announces positive results from phase IIA trial of VALEDIA in prediabetics

VALBIOTIS announced positive results (topline data) for the Phase IIA study of VALEDIA (active substance: TOTUM-63), which evaluated this product's efficacy in a prediabetic population, compared to placebo.

Cantargia announces full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial

Cantargia´s antibody CAN04 (nidanilimab) is investigated in an open label three-armed phase IIa clinical trial, CANFOUR.

GSK begins phase 3 trial for otilimab in patients with rheumatoid arthritis

GSK today announced the start of a phase III clinical development programme with otilimab, an investigational anti-granulocyte macrophage colony-stimulating factor (anti GM-CSF) monoclonal antibody, for patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to disease modifying antirheumatic drugs (DMARD) or targeted therapies.

Roche’s flu drug Xofluza meets primary endpoint in phase III children study

Roche’s flu drug Xofluza (baloxavir marboxil) has achieved primary endpoint in phase III Ministone-2 children study.

Dicerna to begin clinical development of DCR-A1AT for A1AT deficiency-associated liver disease

Dicerna Pharmaceuticals has submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA) last week to conduct a first-in-human Phase 1/2 study of DCR-A1AT, an investigational therapy from the Company’s GalXC technology platform, for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease.

Vedanta Biosciences enrols first patient in VE416 phase 1b/2 food allergy clinical study

Vedanta Biosciences announced the first patient has been enrolled in the Phase 1b/2 clinical study of VE416 in adults and adolescents with a history of peanut allergy.

Xeris doses first patient in phase 2 trial of developmental ready-to-use glucagon in PBH

Xeris Pharmaceuticals has dosed the first subject in a Phase 2 trial with its developmental ready-to-use glucagon in patients who experience hypoglycemic episodes following bariatric surgery.

Lung cancer drug Imfinzi improves overall survival at interim analysis in phase III CASPIAN trial

AstraZeneca announced positive overall survival (OS) results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage small cell lung cancer (SCLC), a disease with significant unmet need and limited treatment options for patients.

Acceleron completes target enrollment in phase 2 trial of Sotatercept in PAH

Acceleron Pharma, a biopharmaceutical company focused on the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept.